Marketing cannabis and the ever-changing U.S. legislative environment
Here is the most up to date listing, by state, as of September 2019. We will update this chart whenever further changes take place.
Marketing
Marketing and the cannabis supply chain: extraction technology
Ancillary opportunities are emerging in the Cannabis supply chain, this one powered by the demand for Edibles and Oils.
Medical cannabis marketing: Germany as an opportunity?
A quick look at Germany suggests it will be a key export market for Canadian manufacturers and producers from other countries – and could be a model followed by other European countries.
Synthetic CBD and its impact on cannabis marketing
Synthetic CBD is poised to impact the medical marijuana business and create another opportunity for cannabis marketers.
Canada’s National Cannabis Survey – a marketing tool
These surveys provide a gateway into knowledge about an emerging and untapped industry.
Keep an eye on marketing opportunities from cannabis reform
The Marijuana Justice Act: One of many potential regulatory changes that the industry, investors and marketers need to watch with the U.S. 2020 election looming.
Celebrities and cannabis marketing
Add “Chief Brand Strategist” to Shawn “Jay-Z” Carter’s bio as he joins up with Caliva, a leading California-based cannabis consumer products company.
Marketing cannabis beverages – friend or foe to the alcohol industry?
Are THC and/or CBD-infused beverages the cannabis products that will really challenge the alcohol industry? Well, they’re beverages too.
Cannabis marketing & the evolving business ecosystem
While the licensed cannabis producers (LPs) seem to attract most of the attention from investors and consumers, don’t overlook the significant business opportunities within the growing and evolving ancillary businesses that service and supply the cannabis ecosystem.
Cannabis marketing and the foggy regulatory landscape
It’s my belief that the FDA will turn a blind eye to CBD-based products, especially at the national retailers as long as the manufacturers do not make unsubstantiated therapeutic claims.